Technology
Health
Pharmaceutical

Moleculin Biotech

$1.29
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.75%) Today
-$0.03 (-2.27%) After Hours

Why Robinhood?

You can buy or sell MBRX and other stocks, options, ETFs, and crypto commission-free!

About

Moleculin Biotech, Inc. Common Stock, also called Moleculin Biotech, is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Read More Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Employees
9
Headquarters
Houston, Texas
Founded
2015
Market Cap
37.66M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
237.06K
High Today
$1.35
Low Today
$1.29
Open Price
$1.33
Volume
32.12K
52 Week High
$2.43
52 Week Low
$0.934

Collections

Technology
Health
Pharmaceutical
Medical
2016 IPO
US
North America

News

Markets InsiderMar 19

Moleculin Announces First Patients Enrolled in Lymphoma Clinical Trial

HOUSTON, March 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that the first two patients have been enrolled in its European clinical trial of WP1220 for the topical treatment of cutaneous T-cell lymphoma (CTCL). "This now marks four clinical trials with patients enrolled," commented Walter Klemp, Moleculin's Chairman and CEO....

159
PR NewswireMar 18

Moleculin Biotech, Inc. to Present at the Oppenheimer 29th Annual Healthcare Conference and the 31st Annual ROTH Conference

HOUSTON, March 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center, today announced that Walter Klemp, Chairman and CEO and Jonathan Foster, Chief Financial Officer, will present at the following investor conferences: Oppenheimer 29 th Annual Hea...

24
MarketBeatMar 6

Stock Price, News, & Analysis for Moleculin Biotech

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and relat...

39

Earnings

-$0.20
-$0.13
-$0.07
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 14, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.